Status:
COMPLETED
Long Term Outcomes in β Thalassemia Major
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago
Conditions:
Thalassemia Major
Eligibility:
All Genders
Up to 30 years
Brief Summary
Beta thalassemia (β-thalassemia) is the most common genetic disease worldwide. Individuals with thalassemia are born with a defect in hemoglobin. Hemoglobin is a protein in red blood cells that carrie...
Detailed Description
Hematopoietic stem cell transplantation (HSCT) is considered a suitable alternative to conservative management which includes chronic transfusion therapy, iron chelation (iron overload) and management...
Eligibility Criteria
Inclusion
- Inclusion for those who underwent HSCT:
- Age 0 to 30 years of age
- \>1 year post-allogeneic HSCT for Beta-Thalassemia. Any donor (sibling or unrelated) and any donor source (bone marrow, peripheral blood, umbilical cord blood) is considered eligible. Any conditioning regimen is considered acceptable for enrollment
- Exclusion:
- \<1 year post-allogeneic HSCT for Beta-Thalassemia
- Patient expired prior to 1 year post-HSCT
- Autologous stem cell transplantation for Beta-Thalassemia
Exclusion
Key Trial Info
Start Date :
June 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2016
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT02307786
Start Date
June 1 2014
End Date
November 30 2016
Last Update
February 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611